checkAd
    NewAmsterdam Pharma Company Aktie
    20,600
     
    EUR
    +0,98 %
    +0,200 EUR
    Letzter Kurs 29.04.24 Lang & Schwarz
    20,400
     
    EUR
    416 STK
    Geldkurs 29.04.24
    20,800
     
    EUR
    416 STK
    Briefkurs 29.04.24
    ISIN: NL00150012L7 · WKN: A3DUAC · Niederlande

    Neueste Nachrichten

    NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
    09.04.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
    01.04.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
    25.03.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
    12.03.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
    28.02.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
    26.02.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
    14.02.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
    13.02.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    01.02.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
    08.01.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Announces 2024 Strategic Priorities
    04.01.24 · globenewswire · NewAmsterdam Pharma Company
    NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
    13.11.23 · globenewswire · NewAmsterdam Pharma Company